The molecular characterization of disease processes has become an indispensable component of current cancer research. The mission of the Proteomics & Metabolomics Shared Resource (PMSR) is to provide state-of-the- art chromatographic and mass spectrometric services for proteomics and metabolomics applications. The PMSR was established in 2006 for proteomics and expanded to metabolomics in 2008. Since the last review, PMSR?s activity and throughput have expanded dramatically; the PMSR provided services to 22 Georgetown Lombardi Comprehensive Cancer Center (LCCC) members in fiscal year (FY) 2017. Radoslav Goldman, PhD, oversaw proteomics operations through 03/2018, at which time he stepped down to focus on directing his newly formed Glycoscience Center. Byers replaced Goldman. Byers is the founder and a former director of the PMSR. Proteomics services include optimizing workflows and developing specialized services, which include identifying proteins and peptides and their modifications and quantification. Targeted liquid chromatography-mass spectrometry (LC-MS) experiments for specific proteins and their modifications facilitate the conduct of translational research applications. Cheema manages the metabolomics component. The metabolomics component includes comprehensive metabolomics and lipidomics profiling services from a variety of matrices, including tissue and cultured cells and biofluids, such as serum, plasma and urine. The PMSR has developed and optimized methods for protein and metabolite extraction from complex matrices such as cells, feces, ductal lavage fluid and cerebrospinal fluid. The proteomics and metabolomics services also include multiple reaction monitoring (MRM)-based targeted quantification, and metabolomics services further include high-resolution MS for small molecules. The Waters Corporation recognized the metabolomics component as a Center of Innovation. Waters has continually supported high-impact science, resulting in multiple extramurally funded grants with a metabolomics focus in at least one specific aim.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA051008-26
Application #
9704646
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
26
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59

Showing the most recent 10 out of 1120 publications